Immune/Inflammatory Disease: Early-Stage R&D Technologies and Dealmaking

Title	Published	Price
Prostate Cancer Drug Discoveries: What the Future Holds By: Espicom Healthcare Intelligence Prostate cancer is the second leading cause of cancer in the US and the third most common cancer worldwide. More than two million men in the US suffer with prostate cancer. Find out more about \| more... Search inside this report	11/5/2009	$2,460.00
BI for Drug Development: Oracle Introduces Clinical Development Analytics By: IDC This IDC Health Insights Perspective highlights the announcement of a dedicated life science business intelligence (BI) solution introduced recently at Oracle OpenWorld 2009 that promises to deliver actionable insights into clinical development processes. Oracle Clinical \| more... Search inside this report	11/1/2009	$1,500.00
Asia Pacific Pharma Sector Analysis By: RNCOS The world continues to witness significant shift in the global pharmaceutical market landscape, with Asia-Pacific emerging as the fastest growing pharmaceutical market over the recent past. With low costs and favorable regulatory environment, the region \| more...	11/1/2009	$1,200.00
Protein Kinase Therapeutics in Oncology - Where to Commercialize? By: BioSeeker Group AB This report comprises defined and up to date development strategies for 409 protein kinase drugs (990 projects) within the portfolio of 160 investigators, from Ceased to Marketed. The report extensively analyses 133 identified targets of \| more...	10/29/2009	$3,500.00
CDK Inhibitors Patent Landscape 2009 By: France Innovation Scientifique et Transfer IP Overview presents a patent landscape analysis of the CDK Inhibitor field. Alterations in CDK activity have been associated in the development of viral infections, neurodegenerative dis orders such as Alzheimer’s disease and proliferative \| more... Search inside this report	10/29/2009	$1,645.00
Pipeline Insight: Colorectal Cancer - Growing trend towards personalized medicine By: Datamonitor Introduction CRC incidence will be over 490,000 cases by 2018 in the seven major markets. This large patient base will translate into a high commercial potential for the development of novel, more effective therapies. Currently, there \| more...	10/21/2009	$11,400.00
Antidiabetics in Australia Market Forecast By: Datamonitor Introduction Datamonitor expects the Australian antidiabetics market to reach $416m by 2018. The growth will be driven by the launch of new drug classes, notably the incretin mimetics, and large growth in patient numbers. Although strongest \| more...	10/20/2009	$5,700.00
Notable News in the Life Sciences: 3Q09 By: IDC This Health Industry Insights Perspective provides an unranked list and assessment of important news and trends reported in July through September 2009. (Note also that progress attained or subsequent news reported after the initial announcement \| more... Search inside this report	10/18/2009	$1,500.00
Pharmaceuticals Wholesaling in Australia - Industry Risk Rating Report By: IBISWorld Industry Risk Ratings Synopsis This Industry Risk Ratings report from IBISWorld evaluates the inherent risks associated with the Pharmaceuticals Wholesaling in Australia industry. Industry Risk is assumed to be 'the difficulty, or otherwise, of the business \| more... Search inside this report	10/17/2009	$810.00
Biomarker and Diagnostic Opportunities in Clinical Research for Neurological Diseases By: Decision Resources Introduction Biomarkers and imaging tools are enabling technologies in today’s clinical research efforts for neurological diseases. Whether to improve upon existing methods for monitoring disease progression or to discover validated measures to detect diseases earlier \| more...	10/13/2009	$2,250.00

Phone: 800.298.5699 (US) or +1.240.747.3093 (Int'l)
Hours: 7:00 a.m. to 7:00 p.m. EST Monday through Friday
Email: customerservice@marketresearch.com
Copyright © 1999-2009, All Rights Reserved, MarketResearch.com
11/22/2009 - 4